- Lexaria’s 2022 R&D efforts saw high levels of success, establishing the company as one of the world’s leaders in the investigation of CBD for controlling human blood pressure and, separately, demonstrating performance enhancements compared to one of the world’s leading anti-seizure medications
- During Q1 2023, Lexaria expects to provide additional results from its hypertension study HYPER-H21-4; complete dosing in the company’s animal dementia and diabetes studies; complete dosing in the human nicotine study NIC-H21-1; and submit and publish additional results in research journals
- Lexaria’s DehydraTECH technology currently has 28 granted patents, with many more pending patents in countries worldwide
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using its patented DehydraTECH(TM) technology to improve the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. In a letter to shareholders last month, Lexaria CEO Chris Bunka provided a thorough strategic update and insight into the company’s plan moving forward.
Mr. Bunka expressed how the current state of the economy has presented challenges to companies, especially during 2022. Still, Lexaria has navigated these challenges well by focusing on the things it can control, such as applied R&D designed to entice others to work with the company commercially. Despite inflation running at a 40-year high and 2022 stock markets experiencing the longest protracted decline since 2008, Lexaria is forging ahead – increasing staff and successfully handling an unprecedented volume of work (https://cnw.fm/JD2q5).
During 2022, Lexaria’s R&D pursuits were a success, firmly establishing the company as one of the world’s leaders in the investigation of cannabidiol (“CBD”) for controlling human blood pressure and demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications. Lexaria expects that 2023 will be full of additional R&D developments.
Lexaria’s expectations for Q1 2023 include the following:
- Additional results from hypertension study HYPER-H21-4
- Dosing completion in the company’s animal dementia study
- Dosing completion in the company’s animal diabetes study
- Dosing completion in human nicotine study NIC-H21-1
- Submissions and publishing of additional results in research journals
Also in 2023, Lexaria expects to file its Investigational New Drug (“IND”) application and receive approval from the US Food and Drug Administration (“FDA”) to commence the IND clinical study. The study will be a major step in the company’s maturation as a pharmaceutical company and will be its primary research focus once it commences.
Lexaria’s DehydraTECH technology currently has 28 granted patents, with many more pending patents in countries worldwide. The technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine, and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. It is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter capsules, pills, tablets, oral suspensions and more.
DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients – increasing effectiveness and improving the way APIs enter the bloodstream. The benefits of DehydraTECH include faster delivery of the drug, increased bioavailability, increased brain absorption, improved drug potency, reduced drug administration costs, and masks unwanted taste, removing the need for additional sweetening ingredients.
Since 2016, Lexaria’s DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and, reduce the time of onset from one to two hours to just minutes.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.
To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.hempwire.com
Do you have a questions or are you interested in working with HW? Ask our Editor
HempWire is part of the InvestorBrandNetwork.